Patent · US Active

Crystalline forms

US10351560B2 · kind B2 · utility

0Cited by

11References

13Claims

0Family size

Assignee

IDORSIA PHARMACEUTICALS LTD · CH

Inventors

Hamed Aissaoui · Allschwil, CH
Christoph Boss · Allschwil, CH
Patrick Bouis · Allschwil, CH
Julien Hazemann · Allschwil, CH
Romain Siegrist · Allschwil, CH
Markus Von Raumer · Allschwil, CH

Key dates

Filing date	Sep 14, 2016
Grant date	Jul 16, 2019
Priority date	—
Expiry date	Sep 14, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.